Should you buy ARGX right now? Stockgaide's algorithm rates ARGX as BUY, with a technical score of 80/100. The 50-day average is above the 200-day average, and RSI sits at 54.8. Wall Street's consensus rating is 1.76/5.
The technical indicators suggest a bullish stance for ARGX. With a technical score of 80 out of 100, the stock sits above both its 50‑day (877.62) and 200‑day (831.13) moving averages, indicating upward momentum. The RSI of 54.8 sits in the neutral zone, and the MACD histogram at –0.2288, while slightly negative, is close to zero, implying the trend is still consolidating rather than reversing.
Fundamentally, ARGX trades at a P/E of 22.29, a valuation that is moderate for a biotech firm with a strong pipeline. Analyst consensus is a 1.76 out of 5, which translates to a “Strong Buy” rating, underscoring confidence in the company’s growth prospects and earnings outlook.
Investors should monitor the upcoming earnings report and any updates on clinical trial milestones, as these will likely drive the next price swing. Pay attention to any changes in the 52‑week range and watch for a potential breakout above the upper bound of 953.58. This is educational content, not investment advice.
Analyst ratings: 23 Buy · 2 Hold · 0 Sell (1 = Strong Buy, 5 = Strong Sell)
Stockgaide's algorithm currently rates ARGX as BUY, with a technical score of 80 out of 100. This is educational content, not investment advice.
ARGX's 50-day moving average (877.62) is above its 200-day moving average (831.13), which points to a medium-term uptrend.
ARGX has a 14-day RSI of 54.8, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
Wall Street analysts covering ARGX have a consensus rating of 1.76 out of 5 (1 = Strong Buy), meaning they lean Buy — 23 Buy · 2 Hold · 0 Sell.
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.
Analyze ARGX now →